<table className="table">
  <caption>
    <p>
      Recommended Pharmacologic Management of COPD by GOLD Classification
    </p>
  </caption>
  <thead>
    <tr>
      <th colSpan="1" rowSpan="1">
        <p>
          Patient Group
        </p>
      </th>
      <th colSpan="1" rowSpan="1">
        <p>
          Recommended Therapy
        </p>
      </th>
      <th colSpan="1" rowSpan="1">
        <p>
          Alternative or Additional Therapy
        </p>
      </th>
      <th colSpan="1" rowSpan="1">
        <p>
          Other Considerations
        </p>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr className="group_1-1 row-odd">
      <td colSpan="1" rowSpan="1">
        <p>
          A
        </p>
      </td>
      <td colSpan="1" rowSpan="1">
        <p>
          Short-acting bronchodilator
          <i>
            or
          </i>
        </p>
        <p>
          Long-acting bronchodilator
        </p>
      </td>
      <td colSpan="1" rowSpan="1">
        <p>
          Evaluate effect of therapy and continue, stop, or try alternative bronchodilator as appropriate
        </p>
      </td>
      <td colSpan="1" rowSpan="1">
        <p>
          All patients in this group should receive bronchodilator therapy based on its effect on dyspnea; therapy should be continued if symptomatic benefit is documented
        </p>
      </td>
    </tr>
    <tr className="group_1-2 row-even">
      <td colSpan="1" rowSpan="1">
        <p>
          B
        </p>
      </td>
      <td colSpan="1" rowSpan="1">
        <p>
          LABA+LAMA
        </p>
      </td>
      <td colSpan="1" rowSpan="1">
        <p>
          If a LABA+LAMA combination is not appropriate, there is no evidence to recommend one agent over the other; choice should depend on the patient's perception of symptom relief
        </p>
      </td>
      <td colSpan="1" rowSpan="1">
        <p>
          Long-acting inhaled bronchodilators are superior to short-acting bronchodilators received as needed
        </p>
        <p>
          No evidence supports use of one class of long-acting bronchodilators over another for initial relief of symptoms in this group
        </p>
        <p>
          Patients in group B are likely to have comorbidities that affect symptoms and prognosis, and these should be investigated.
        </p>
      </td>
    </tr>
    <tr className="group_1-3 row-odd">
      <td colSpan="1" rowSpan="1">
        <p>
          E
        </p>
      </td>
      <td colSpan="1" rowSpan="1">
        <p>
          LABA+LAMA
        </p>
        <p>
          LABA+LAMA+ICS
          <sup>
            a
          </sup>
        </p>
      </td>
      <td colSpan="1" rowSpan="1">
        <p>
          If exacerbations continue, consider:
        </p>
        <p>
          Roflumilast (patients with an FEV1 &lt;50% of predicted and chronic bronchitis, particularly if ≥2 exacerbations or ≥1 hospitalization in past year)
        </p>
        <p>
          <i>
            or
          </i>
        </p>
        <p>
          Macrolide therapy (best evidence supports use of azithromycin)
        </p>
        <p>
          <i>
            or
          </i>
        </p>
        <p>
          Dupilumab (patients with chronic bronchitis)
          <sup>
            a
          </sup>
        </p>
      </td>
      <td colSpan="1" rowSpan="1">
        <p>
          Patients with concomitant asthma should receive an ICS
        </p>
      </td>
    </tr>
  </tbody>
</table>
